奥扎格雷钠联合灯盏花素注射液治疗急性脑梗死的Meta分析

Meta Analysis of Sodium Ozagrel Combined with Breviscapine Injection in the Treatment of Acute Cerebral Infarction

目的:系统评价奥扎格雷钠联合灯盏花素注射液治疗急性脑梗死的临床疗效与安全性。方法:检索国内外多个数据库中公开发表的关于奥扎格雷钠联合灯盏花素治疗急性脑梗死的临床随机对照试验的相关文献,依据纳入、排除标准筛选文献应用Review Manager5.3进行Meta分析。结果:共纳入19个随机对照试验,分析显示,奥扎格雷钠联合灯盏花素注射液治疗急性脑梗死的神经功能缺损临床疗效的比值比(OR)合并值为4.46(95%可信区间为3.16~5.64)。神经功能缺损评分疗效加权均数差(WMD)合并值为-4.79(95%可信区间为-5.47^-4.12)。结论:奥扎格雷钠联合灯盏花素注射液治疗急性脑梗死有一定疗效,且安全、不良反应较少,但由于所选样本质量偏低,尚需进一步进行严格的,多中心的随机双盲对照试验来验证。

Objective： To evaluate the clinical curative effect and the safety of Sodium Ozagrel combined with Breviscapine Injection for the treatment of acute cerebral infarction （ACI）. Methods： The randomized con- trolled clinical trials of Sodium Ozagrel combined with Breviscapine Injection for the treatment of ACI searched by computed-based online search, and the data was statistically analyzed by Review ManagerS.3. Results： The results showed that there were 19 literatures which incorporated by Meta-analysis. The analysis showed that the OR （95%C/） was 4.46 （3.16-5.64）, WMD （95% C/） was -4.79 （-5.47--4.12）. Conclusion： The Sodium Ozagrel combined with Breviscapine Injection has confirmative curative effect on the treatment of ACI. It is safe and has less adverse effect. However, there still need some strict and multicentre randomized double-mind control tests to be carried out, in order to provide more effective and convinced evidence.